Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1971 1
1975 2
1976 3
1977 5
1978 6
1979 4
1980 7
1981 4
1982 3
1983 11
1984 4
1985 6
1986 7
1987 10
1988 6
1989 15
1990 15
1991 4
1992 10
1993 15
1994 10
1995 7
1996 5
1997 11
1998 9
1999 13
2000 11
2001 12
2002 14
2003 23
2004 12
2005 23
2006 22
2007 21
2008 24
2009 25
2010 38
2011 40
2012 58
2013 58
2014 49
2015 71
2016 63
2017 53
2018 79
2019 80
2020 107
2021 67
2022 64
2023 75
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

1,135 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypertrophic cardiomyopathy 13"
Page 1
Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy.
Ranjbarvaziri S, Kooiker KB, Ellenberger M, Fajardo G, Zhao M, Vander Roest AS, Woldeyes RA, Koyano TT, Fong R, Ma N, Tian L, Traber GM, Chan F, Perrino J, Reddy S, Chiu W, Wu JC, Woo JY, Ruppel KM, Spudich JA, Snyder MP, Contrepois K, Bernstein D. Ranjbarvaziri S, et al. Circulation. 2021 Nov 23;144(21):1714-1731. doi: 10.1161/CIRCULATIONAHA.121.053575. Epub 2021 Oct 21. Circulation. 2021. PMID: 34672721 Free PMC article.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a complex disease partly explained by the effects of individual gene variants on sarcomeric protein biomechanics. ...METHODS: We performed a comprehensive multiomics profile of the molecular (transcripts, metabolites, …
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a complex disease partly explained by the effects of individual gene variants …
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.
Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, Garcia-Pavia P, Lakdawala NK, Nagueh SF, Rader F, Tower-Rader A, Turer AT, Coats C, Fifer MA, Owens A, Solomon SD, Watkins H, Barriales-Villa R, Kramer CM, Wong TC, Paige SL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham T; REDWOOD-HCM Steering Committee and Investigators. Maron MS, et al. J Am Coll Cardiol. 2023 Jan 3;81(1):34-45. doi: 10.1016/j.jacc.2022.10.020. J Am Coll Cardiol. 2023. PMID: 36599608 Free article. Clinical Trial.
BACKGROUND: Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-class cardiac myosin inhibitor, may lower gradients and improve symptoms in these p …
BACKGROUND: Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophi …
Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Wheeler MT, Jacoby D, Elliott PM, Saberi S, Hegde SM, Lakdawala NK, Myers J, Sehnert AJ, Edelberg JM, Li W, Olivotto I. Wheeler MT, et al. Eur J Heart Fail. 2023 Feb;25(2):260-270. doi: 10.1002/ejhf.2737. Epub 2023 Feb 1. Eur J Heart Fail. 2023. PMID: 36404399 Free article. Clinical Trial.
AIMS: In the EXPLORER-HCM trial, mavacamten improved exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten effects on the primary endpoint, a composite of peak oxygen consumption (VO(2) ) and New York Heart Associ …
AIMS: In the EXPLORER-HCM trial, mavacamten improved exercise capacity and symptoms in patients with obstructive hypertrophic card …
Energetic drain driving hypertrophic cardiomyopathy.
Sequeira V, Bertero E, Maack C. Sequeira V, et al. FEBS Lett. 2019 Jul;593(13):1616-1626. doi: 10.1002/1873-3468.13496. Epub 2019 Jul 4. FEBS Lett. 2019. PMID: 31209876 Free article. Review.
Hypertrophic cardiomyopathy (HCM) is the most common form of hereditary cardiomyopathy and is mainly caused by mutations of genes encoding cardiac sarcomeric proteins. ...
Hypertrophic cardiomyopathy (HCM) is the most common form of hereditary cardiomyopathy and is mainly caused by mutation …
Update on hypertrophic cardiomyopathy and a guide to the guidelines.
Sen-Chowdhry S, Jacoby D, Moon JC, McKenna WJ. Sen-Chowdhry S, et al. Nat Rev Cardiol. 2016 Nov;13(11):651-675. doi: 10.1038/nrcardio.2016.140. Epub 2016 Sep 29. Nat Rev Cardiol. 2016. PMID: 27681577 Review.
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disorder, affecting 1 in 500 individuals worldwide. ...
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disorder, affecting 1 in 500 individuals worldwi …
Apical Aneurysms and Mid-Left Ventricular Obstruction in Hypertrophic Cardiomyopathy.
Sherrid MV, Bernard S, Tripathi N, Patel Y, Modi V, Axel L, Talebi S, Ghoshhajra BB, Sanborn DY, Saric M, Adlestein E, Alvarez IC, Xia Y, Swistel DG, Massera D, Fifer MA, Kim B. Sherrid MV, et al. JACC Cardiovasc Imaging. 2023 May;16(5):591-605. doi: 10.1016/j.jcmg.2022.11.013. Epub 2023 Jan 11. JACC Cardiovasc Imaging. 2023. PMID: 36681586
BACKGROUND: Apical left ventricular (LV) aneurysms in hypertrophic cardiomyopathy (HCM) are associated with adverse outcomes. ...METHODS: The authors analyzed echocardiographic and cardiac magnetic resonance examinations of patients with aneurysms from 3 dedicated p …
BACKGROUND: Apical left ventricular (LV) aneurysms in hypertrophic cardiomyopathy (HCM) are associated with adverse outcomes. …
Risk of Sudden Death in Patients With RASopathy Hypertrophic Cardiomyopathy.
Lynch A, Tatangelo M, Ahuja S, Steve Fan CP, Min S, Lafreniere-Roula M, Papaz T, Zhou V, Armstrong K, Aziz PF, Benson LN, Butts R, Dragulescu A, Gardin L, Godown J, Jeewa A, Kantor PF, Kaufman BD, Lal AK, Parent JJ, Richmond M, Russell MW, Balaji S, Stephenson EA, Villa C, Jefferies JL, Whitehill R, Conway J, Howard TS, Nakano SJ, Rossano J, Weintraub RG, Mital S. Lynch A, et al. J Am Coll Cardiol. 2023 Mar 21;81(11):1035-1045. doi: 10.1016/j.jacc.2023.01.012. J Am Coll Cardiol. 2023. PMID: 36922089 Free article.
BACKGROUND: Genetic defects in the RAS/mitogen-activated protein kinase pathway are an important cause of hypertrophic cardiomyopathy (RAS-HCM). Unlike primary HCM (P-HCM), the risk of sudden cardiac death (SCD) and long-term survival in RAS-HCM are poorly understoo …
BACKGROUND: Genetic defects in the RAS/mitogen-activated protein kinase pathway are an important cause of hypertrophic cardiomyopa …
Apical variant hypertrophic cardiomyopathy "multimodality imaging evaluation".
Huang G, Fadl SA, Sukhotski S, Matesan M. Huang G, et al. Int J Cardiovasc Imaging. 2020 Mar;36(3):553-561. doi: 10.1007/s10554-019-01739-x. Epub 2019 Dec 18. Int J Cardiovasc Imaging. 2020. PMID: 31853820 Review.
Apical variant hypertrophic cardiomyopathy (AHCM) is characterized by asymmetric hypertrophy of the left ventricular (LV) apex. ...
Apical variant hypertrophic cardiomyopathy (AHCM) is characterized by asymmetric hypertrophy of the left ventricular (LV) apex …
Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines.
Wang J, Yang S, Ma X, Zhao K, Yang K, Yu S, Yin G, Dong Z, Song Y, Cui C, Li J, Wang C, Hao J, Lu M, Chen X, Zhao S. Wang J, et al. Eur Heart J. 2023 Dec 1;44(45):4781-4792. doi: 10.1093/eurheartj/ehad581. Eur Heart J. 2023. PMID: 37795986
BACKGROUND AND AIMS: Identifying patients with hypertrophic cardiomyopathy (HCM) who are candidates for implantable cardioverter defibrillator (ICD) implantation in primary prevention for sudden cardiac death (SCD) is crucial. ...Patients suffering from SCD had high …
BACKGROUND AND AIMS: Identifying patients with hypertrophic cardiomyopathy (HCM) who are candidates for implantable cardiovert …
Exercise and myocardial injury in hypertrophic cardiomyopathy.
Cramer GE, Gommans DHF, Dieker HJ, Michels M, Verheugt F, de Boer MJ, Bakker J, Fouraux MA, Timmermans J, Kofflard M, Brouwer M. Cramer GE, et al. Heart. 2020 Aug;106(15):1169-1175. doi: 10.1136/heartjnl-2019-315818. Epub 2020 Jan 30. Heart. 2020. PMID: 32001622 Free PMC article.
OBJECTIVE: Troponin and high signal intensity on T2-weighted (HighT2) cardiovascular magnetic resonance imaging (CMRi) are both markers of myocardial injury in hypertrophic cardiomyopathy (HCM). The interplay between exercise and disease development remains uncertai …
OBJECTIVE: Troponin and high signal intensity on T2-weighted (HighT2) cardiovascular magnetic resonance imaging (CMRi) are both markers of m …
1,135 results